第80回日本血液学会学術集会 演題応募カテゴリー …

1 1 hematopoietic cell differentiation9 self-renewal2 hematopoietic microenvironment10 transcriptional regulation3 hematopoietic stem cell11 epigenetics4 hematopoietic progenitor cell12 cell cycle5 niche cell13 cell death6 hematopoietic development14 cell adhesion7 ES/iPS )pluripotent stem cell15 others8 cytokine/chemokine1 erythropoiesis11 pathophysiology2 hemoglobin12 disease model3 iron metabolism13 / pharmacological analysis4 erythrocyte membrane14 / / clinical feature/biomarker/prognostic factor5 heme synthesis15 / therapeutic agents and strategy (including transplantation)6 erythropoietin16 / clinical trial/ multi-center study7 refractory anemia17 case report8 aplastic anemia18 epidemiology9 inherited bone marrow failure19 others10 hemolytic anemia2. Erythrocyte / Erythroid Disorders / Bone Marrow Failure1.

2 ( ) Hematopoietic System / Hematopoietic Stem Cell 80 JSH2018 Abstract Submission Categories and Keywords1/61 AML10 pathophysiology2 APL11 disease model3 gene mutation12 / pharmacological analysis4 chromosomal abnormality13 / / clinical feature/biomarker/prognostic factor5 epigenetic abnormality14 / therapeutic agents and strategy (including transplantation)6 leukemic stem cell15 / clinical trial/ multi-center study7 multi-drug combinational chemotherapy16 case report8 molecular target therapy17 epidemiology9 / novel therapeutic agent/novel therapy18 others1 chronic myelloid leukemia13 quality of life2 chromosomal abnormality14 / novel therapeutic agent/novel therapy3 gene mutation15 pathophysiology4 epigenetic abnormality16 disease model5 leukemic stem cell17 / pharmacological analysis6 molecular target therapy18 / / clinical feature/biomarker/prognostic factor7 tyrosine kinase inhibitor (TKI)19 / therapeutic agents and strategy (including transplantation)8 cytogenetic response20 / clinical trial/multicenter trials9 molecular response21 case report10 minimal residual disease (MRD)

3 22 epidemiology11 treatment-free remission23 others12 anti-tumor immune reaction3. AMLM yeloid Neoplasms: AML4-A. CMLM yeloid Neoplasms: CML2/61 myelodysplastic syndromes13 tyrosine kinase inhibitor (TKI)2 myeloproliferative neoplasm (MPN)14 / novel therapeutic agent/novel therapy3 ( polycythemia vera (PV)15 pathophysiology4 essential thrombocythemia (ET)16 disease model5 primary myelofibrosis (PMF)17 / pharmacological analysis6 MPN (other forms)18 / / clinical feature/biomarker/prognostic factor7 / MDS/MPN19 / therapeutic agents and strategy (including transplantation)8 gene mutation20 / clinical trial/multicenter trials9 chromosomal abnormality21 case report10 epigenetic abnormality22 epidemiology11 leukemic stem cell23 others12 molecular target therapy1 acute lymphoblastic leukemia12 / novel therapeutic agent/novel therapy2 chronic lymphocytic leukemia13 pathophysiology3 chromosomal abnormality14 disease model4 gene mutation15 / pharmacological analysis5 epigenetic abnormality16 / / clinical feature/biomarker/prognostic factor6 leukemic stem cell17 / therapeutic agents and strategy (including transplantation)7 molecular target therapy18 / clinical trial/multicenter trials8 tyrosine kinase inhibitor (TKI)19 case report9 antibody therapy20 epidemiology10 T Car-T cell21 others11 minimal resifual disease (MRD)4-B.)

4 MPN,MDS Myeloid Neoplasms: MPN, MDS and others5-A. Lymphoid Malignancies: ALL / CLL3/61 stem cell(cellular/molecular function)9 / pharmacological analysis2 chromosomal abnormality10 / new agent development3 gene mutation11 / novel therapeutic agent/novel therapy4 epigenetic abnormality12 pathophysiology5 ( pathophysiology13 disease model6 protein/surface antigen expression14 / pharmacological analysis7 gene expression15 / / clinical feature/biomarker/prognostic factor8 disease model16 / therapeutic agents and strategy (including transplantation)1 malignant lymphoma14 Hodgkin lymphoma2 B diffuse large B-cell lymphoma15 immunodeficiency-associated lymphoproliferative disorder3 follicular lymphoma16 histiocytic disorder4 MALT MALT lymphoma17 pathophysiology5 mantle cell lymphoma18 / / clinical feature/biomarker/prognostic factor6 / B Burkitt lymphoma/highly aggressive lymphoma19 / therapeutic agents and strategy (including transplantation)7 macroglobulinemia20 / new agent/treatment8 B B-cell lymphoma, other types21 immune checkpoint inhibitor9 T peripheral T-cell lymphoma, not otherwise specified22 supportive care10 lymphoblastic lymphoma23 / clinical trial11 T adult T-cell leukemia-lymphoma24 case report12NK/T NK/T-cell lymphoma25 epidemiology13 T T-cell lymphoma, other types26 others5-B.)

5 Lymphoid Malignancies: Malignant Lymphoma -Basic Research-5-C. Lymphoid Malignancies: Malignant Lymphoma -Clinical Research-4/61 multiple myeloma11 / pharmacological analysis2 M monoclonal gammopathy of undetermined significance (MGUS)12 minimal resifual disease (MRD)3 smoldering myeloma13 disease model4 myeloma-related diseases (amyloidosis, Castleman disease, etc)14 )novel drug development (basic)5 chromosomal abnormality15 / novel therapeutic agent/novel therapy6 gene mutation16 / clinical trial7 epigenetic abnormality17 case report8 athophysiology18 epidemiology9 / / clinical feature/biomarker/prognostic factor19 others10 / )therapeutic agents and strategy (including transplantation)1 thrombus basics 14 antiphospholipid syndrome APS 2 hemostasis15 thrombosis clinics 3 blood vessel16 antithrombotic therapy4 platelet17 disseminated intravascular coagulation (DIC)

6 5 megakaryocyte18 idiopathic thrombocytopenic purpura (ITP)6 coagulation19 thrombotic thrombocytopenic purpura (TTP)7 coagulation factor20 heparin induced thrombocytopenia HIT 8 hemophilia21 hereditary diseases9 coagulation inhibitor22 / new agent/treatment10 fibrinolysis23 case report11 vascular endothelial cell24 epidemiology12 inhibitor for coagulation factor25 others13 laboratory test of thrombosis and hemostasis6. Lymphoid Malignancies: Multiple Myeloma and others7. Thrombus / Hemostasis / Blood Vessel5/61 stem ell biology11 QOLlate complications and QOL2 stem cell mobiliztion and harvest12 ( )supportive care3 stem cell source13 noninfectious co plications4 histocompatibility antigen14 minimal residual disease and relapse5 HLA haplo-identical transplantation15 clinical autologous transplantation: outcome6 Conditioning Regimens16 clinical allogeneic transplantation.

7 Outcome7 transplant immunology17 / clinical trial8 engraftment and immune reconstitution18 case report9 GVHD acute GVHD19 epidemiology10 GVHD chronic GVHD20 others1 primary immunodeficiency6 gene therapy2 immune regulation7 transfusion3 cancer antigen8 regenerative medicine4 cancer vaccine9 / clinical trial/multicenter trials5 cell therapy10 case report1 / bacterial infection/anti-bacterial drug6 febrile neutropenia2 / viral infection/anti-viral drug7 opportunistic infection3 virus reactivation8 catheter-related infection4 / fungal infection/anti-fungal drug9 therapy (preventive, empiric, targeted)5 sepsis10 case report1-10 8. Hematopoietic Stem Cell Transplantation / 9. Immunity / Cell and Gene therapy / Transfusion / 1-7 10. Infection / Infectious Disease11.

8 Pediatric Hematology6/6